Monoclonal Antibodies
Paclitaxel +/− Cixutumumab for Esophageal Cancer
This trial is testing how well paclitaxel (a chemotherapy drug) works with or without cixutumumab (a protein-blocking drug) to treat patients with esophageal or gastroesophageal junction cancer that has spread to other parts of the body.
Platinum-based Chemotherapy
Radiation Therapy + Chemotherapy for Cervical Cancer
This trial compares radiation therapy with chemotherapy to radiation therapy alone to see which is more effective in treating patients with early cervical cancer who have already undergone surgery.
Popular Filters
Trials for Ductal Carcinoma Patients
Hormone Therapy
Hormone Therapy + Immunotherapy for Advanced Breast Cancer
This trial is testing tamoxifen citrate or letrozole with or without bevacizumab to treat stage IIIB or IV breast cancer. Estrogen fuels breast cancer cell growth, so hormone therapy with tamoxifen or letrozole can block estrogen and stop tumor growth. Bevacizumab is an immunotherapy that may help the body's immune system fight the cancer. Researchers want to see if it is more effective with or without bevacizumab.
Angiogenesis Inhibitor
Cediranib + Olaparib for Ovarian and Breast Cancer
This trial is testing the combination of two drugs, cediranib maleate and olaparib, to treat patients with certain types of recurrent cancer. Cediranib maleate cuts off the blood supply to cancer cells, while olaparib stops them from repairing their DNA. The trial aims to find the best dose and see if the combination works better than using olaparib by itself. Combining cediranib, which cuts off the blood supply to cancer cells, with olaparib, which stops cancer cells from repairing their DNA, may help patients live longer without their cancer getting worse.
Trials for Breast Cancer Patients
Hormone Therapy
Hormone Therapy + Immunotherapy for Advanced Breast Cancer
This trial is testing tamoxifen citrate or letrozole with or without bevacizumab to treat stage IIIB or IV breast cancer. Estrogen fuels breast cancer cell growth, so hormone therapy with tamoxifen or letrozole can block estrogen and stop tumor growth. Bevacizumab is an immunotherapy that may help the body's immune system fight the cancer. Researchers want to see if it is more effective with or without bevacizumab.
Angiogenesis Inhibitor
Cediranib + Olaparib for Ovarian and Breast Cancer
This trial is testing the combination of two drugs, cediranib maleate and olaparib, to treat patients with certain types of recurrent cancer. Cediranib maleate cuts off the blood supply to cancer cells, while olaparib stops them from repairing their DNA. The trial aims to find the best dose and see if the combination works better than using olaparib by itself. Combining cediranib, which cuts off the blood supply to cancer cells, with olaparib, which stops cancer cells from repairing their DNA, may help patients live longer without their cancer getting worse.
Trials for ER Positive Patients
Hormone Therapy
Hormone Therapy + Immunotherapy for Advanced Breast Cancer
This trial is testing tamoxifen citrate or letrozole with or without bevacizumab to treat stage IIIB or IV breast cancer. Estrogen fuels breast cancer cell growth, so hormone therapy with tamoxifen or letrozole can block estrogen and stop tumor growth. Bevacizumab is an immunotherapy that may help the body's immune system fight the cancer. Researchers want to see if it is more effective with or without bevacizumab.
Poly (ADP-ribose) polymerase (PARP) inhibitor
Veliparib + Carboplatin for Breast Cancer
This trial is testing the combination of veliparib and carboplatin to treat patients with HER2-negative breast cancer that has spread. Veliparib may help carboplatin kill more cancer
Hormone Therapy
Fulvestrant + Anastrozole for Breast Cancer
This trial is testing whether neoadjuvant endocrine therapy with fulvestrant or the combination of anastrozole and fulvestrant is better than anastrozole when given before surgery to shrink the cancer and stop it from growing.
Phase 3 Trials
Hormone Therapy
Hormone Therapy + Immunotherapy for Advanced Breast Cancer
This trial is testing tamoxifen citrate or letrozole with or without bevacizumab to treat stage IIIB or IV breast cancer. Estrogen fuels breast cancer cell growth, so hormone therapy with tamoxifen or letrozole can block estrogen and stop tumor growth. Bevacizumab is an immunotherapy that may help the body's immune system fight the cancer. Researchers want to see if it is more effective with or without bevacizumab.
Alkylating agents
Chemotherapy + Bevacizumab for Head and Neck Cancers
This trial is testing chemotherapy with or without bevacizumab to see how well it works in treating patients with head and neck squamous cell carcinoma that has come back or spread to other parts of the body.
Alkylating agents
Chemotherapy +/− Bevacizumab for Ovarian Cancer
This trial is studying carboplatin, paclitaxel, and gemcitabine hydrochloride given together with or without bevacizumab after surgery to treat patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer.
Trials With No Placebo
Microtubule Inhibitor
Eribulin Mesylate for Advanced Bladder Cancer
This trial looks at the effect of eribulin mesylate on patients with cancer of the urothelium that has spread to nearby tissue or to other places in the body and kidney dysfunction.
View More Related Trials
Frequently Asked Questions
Introduction to head and neck squamous cell carcinoma
What are the top hospitals conducting head and neck squamous cell carcinoma research?
When it comes to cutting-edge clinical trials for head and neck squamous cell carcinoma, several top hospitals are leading the way in research and innovation. Located in Duarte, California, City of Hope Comprehensive Cancer Center offers an impressive 19 ongoing trials focused specifically on this type of cancer. While they have yet to conduct any previous studies in this area, their dedication to combating head and neck squamous cell carcinoma is evident.
Similarly committed to finding new treatments and strategies is the University of California Davis Comprehensive Cancer Center in Sacramento. With 19 active clinical trials solely dedicated to head and neck squamous cell carcinoma, they too have not conducted any previous studies but remain steadfast in their pursuit of advancements.
Heading over to Houston, Texas, we find M D Anderson Cancer Center making significant strides with 18 ongoing clinical trials for head and neck squamous cell carcinoma. Like the other hospitals mentioned above, they also do not have a recorded history of past trials specific to this condition; however, their current efforts showcase their commitment towards future breakthroughs.
Closer to Los Angeles lies Providence Saint Joseph Medical Center/Disney Family Cancer Center located in Burbank where researchers are actively conducting 18 clinical trials focusing on head and neck squamous cell carcinoma treatment without having carried out prior investigations thus far.
Finally reaching Berkeley's Alta Bates Summit Medical Center-Herrick Campus which contributes significantly as well through its participation involving seventeen concurrent tests pertaining exclusively towards patients suffering from Head & Neck Squamous Cell Carcinoma despite lack historical data regarding earlier undertakings until now
These esteemed institutions serve as beacons of hope for those battling or affected by head and neck squamous cell carcinoma. Through collaborative efforts within these medical centers across various locations nationwide there exists strong belief that every trial brings us closer towards pioneering discoveries that would potentially revolutionize treatment options available thereby enhancing quality life countless individuals grappling such ailment face
Which are the best cities for head and neck squamous cell carcinoma clinical trials?
When it comes to head and neck squamous cell carcinoma clinical trials, several cities in the United States emerge as key hubs for research and treatment. Anchorage, Alaska boasts an impressive 84 active trials, focusing on the efficacy of Bevacizumab, Tamoxifen Citrate, Arm III (anastrozole and fulvestrant), among others. Oakland, California follows closely behind with 75 ongoing studies exploring treatments such as Bevacizumab, Trastuzumab, Paclitaxel. Additionally, Denver, Colorado has 73 active trials investigating the potential benefits of Bevacizumab,Paclitaxel,Therapeutic Conventional Surgery,and more. These cities offer individuals diagnosed with head and neck squamous cell carcinoma access to cutting-edge clinical trials that pave the way for advancements in care and improved outcomes.
Which are the top treatments for head and neck squamous cell carcinoma being explored in clinical trials?
Clinical trials for head and neck squamous cell carcinoma are investigating several promising treatments. Leading the pack is pembrolizumab, a groundbreaking immunotherapy drug that has shown significant efficacy in multiple trials. Another contender is cetuximab, a targeted therapy specifically designed to tackle this type of cancer. Additionally, researchers are exploring the potential of combination therapies such as docetaxel plus cisplatin and radiation therapy with chemotherapy drugs like fluorouracil. These innovative approaches bring hope for improved outcomes in patients battling head and neck squamous cell carcinoma.
What are the most recent clinical trials for head and neck squamous cell carcinoma?
Promising advancements in the treatment of head and neck squamous cell carcinoma have emerged from recent clinical trials. In particular, Nivolumab has shown encouraging results as a potential therapy for this type of cancer. Additionally, various treatment combinations involving cisplatin, docetaxel, nintedanib, crizotinib, erlotinib hydrochloride, and nab-paclitaxel are being investigated to improve outcomes for patients with head and neck squamous cell carcinoma. These trials offer hope for enhanced therapeutic options that can make a significant difference in the lives of individuals affected by this challenging disease.
What head and neck squamous cell carcinoma clinical trials were recently completed?
Several clinical trials focusing on head and neck squamous cell carcinoma have recently concluded, showcasing advancements in treatment options for this aggressive form of cancer. Notably, a trial sponsored by the University of Texas MD Anderson Cancer Center investigating pembrolizumab reached completion in September 2021. Another significant milestone was achieved with the conclusion of a study led by Memorial Sloan Kettering Cancer Center, evaluating the efficacy of nivolumab combined with ipilimumab in treating advanced-stage head and neck squamous cell carcinoma. These completed trials demonstrate ongoing efforts to improve outcomes and enhance therapeutic strategies against this challenging disease.